Prior Authorization for Istodax

The medication Istodax (C0965) will require prior authorization through Oncology Analytics when used for oncology purposes for members of Harvard Pilgrim’s commercial and StrideSM (HMO) Medicare Advantage plans, effective Nov. 1, 2021.

Oncology Analytics conducts medical review of chemotherapeutic protocols (chemotherapy, support and symptom management drugs) and radiation treatment plans for Harvard Pilgrim members with a cancer diagnosis that requires these services.

You can view prior authorization criteria for oncology drugs, as well as any recent coding updates, on the Oncology Analytics website. To request authorization, contact Oncology Analytics by fax (800-264-6128), phone (877-222-2021), or online via HPHConnect.


Publication Information

Annmarie Dadoly,
Editor

Joseph O’Riordan,
Writer

Kristin Edmonston,
Production Coordinator